A Phase 1 interventional study of PF-05212384 (also known as PKI-587) in Neoplasms, sponsored by Pfizer. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-11-02.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a two-part study of a compound called PF-05212384 (also known as PKI-587). The purpose of part 1 is to identify the Maximum Tolerated Dose (MTD) of PF-05212384 using a Continual Reassessment Method (CRM). Part 1 will include subjects with any solid tumor. In Part 2 two cohorts will be enrolled. One cohort will assess safety, tolerability and preliminary efficacy in 20 subjects at the MTD and will include subjects with breast cancer, ovarian cancer, endometrial cancer, colorectal cancer renal cancer or glioblastoma (a type of brain tumor). The other cohort will include 5 to 15 subjects with any type of tumor who consent to provide tumor biopsies while participating in the study.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 78 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-05212384 (also known as PKI-587)
Drug: PF-05212384 (also known as PKI-587)
Intravenous dosing once weekly infusion
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category. AEs included both serious and non-serious adverse events.
Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
Number of Participants With Laboratory Abnormalities
Criteria for laboratory test abnormality: hematology (hemoglobin \[less than {\<} 0.8\*lower limit of normal {LLN}\], platelets \[\<0.5\*LLN or greater than {\>} 1.75\*upper limit of normal {ULN}\], white blood cells \[\<0.6\*LLN or \>1.5\*ULN\], lymphocytes \[\<0.8\*LLN or \>1.2\*ULN\], total neutrophils \[\<0.8\*LLN or \>1.2\*ULN\], basophils, eosinophils, monocytes \[\>1.2\*ULN\]); coagulation \[partial thromboplastin time, prothrombin (PT), PT international ratio \[\>1.1\*ULN\]); liver function (total bilirubin \[\>1.5\*ULN\], aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase \[\>0.3\*ULN\], total protein, albumin \[\<0.8\*LLN or \>1.2\*ULN\]).
Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: Grade 3 nonhematologic AE (including nausea, vomiting, or diarrhea despite optimal therapy; or greater than or equal to \[\>=\] grade 3 asthenia \>2 days; or fasting serum glucose \>250 milligrams per deciliter (mg/dL) despite optimal therapy); \>=Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding; Grade 4 neutropenia lasting more than 7 days; Febrile neutropenia; other Grade 4 hematologic AE; delay of treatment \>2 consecutive weeks due to toxicity. Grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Time frame: Baseline up to Day 28
Recommended Phase-2 Dose (RP2D)
RP2D of PF-05212384 was determined based on the safety profile including laboratory and clinical assessments and pharmacodynamics findings.
Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
Maximum Observed Plasma Concentration (Cmax) of PF-05212384: Single and Multiple Dose
Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05212384: Single Dose
Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (Clast).
Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1
Plasma Decay Half-Life (t1/2) of PF-05212384: Single and Multiple Dose
Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-05212384: Single Dose
AUCinf= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - inf).
Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-05212384: Single and Multiple Dose
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 168 hours (1 Week). For Cycle 2, the last PK sample for parameter calculations was on 120 hours after the Day 1 dose, however AUCtau was extrapolated to 168 hours using t1/2.
Time frame: Cycle 1: predose, 0.5, 2, 3, 6, 24, 72, 120 and 168 hours postdose on Day 1; Cycle 2: predose, 0.5, 24, 72, 120 hours postdose on Day 1
Number of Participants With Maximum Increase From Baseline in Corrected QT Interval
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of Participants with maximum increase from baseline in QTcB and QTcF of \< 30 msec, between \<=30 to \<60 msec and \>=60 were reported.
Time frame: Baseline up to Cycle 14 (each cycle is 28 days)
Change From Baseline in Serum Glucose at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
Time frame: Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)
Change From Baseline in Serum Insulin at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
Time frame: Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)
Change From Baseline in Serum C-peptide at Day 2 of Cycle 1, Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and End of Treatment
Time frame: Baseline, Day 2 of Cycle 1, thereafter Day 1 of Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 (each cycle 28 days) , end of treatment visit (up to Cycle 14)
Change From Baseline in Hair Follicle Biopsy Biomarkers at Cycle 1 Day 1
Analysis of hair follicles was conducted using a Reverse Phase Microarrays (RPMA) assay. Phosphoprotein biomarkers measured were pAkt S473, pAkt T308, pStat3 (Y705), Ki-67, and pPRAS40 (T246).
Time frame: Baseline, 2, 3 and 72 hours (H) postdose on Day 1 of Cycle 1
Change From Baseline in Fresh Tumor Biopsy Biomarkers at Cycle 1 Day 22
Tumor biopsies were taken from participants of reporting arm PF-05212384 154 mg dose level at baseline and at Cycle 1/Day 22. Biopsies were fixed in optimal cutting temperature compound and analyzed via RPMA. The biomarkers tested were phosphorylated versions of the proteins: AKT S473, AKT T308, FKHR T24 / FKHR1 T32, and STAT3. This outcome measure was planned to be analyzed only for the reporting arm Part 1 and 2: PF-05212384 154 mg, as pre-specified in protocol.
Time frame: Baseline, Day 22 of Cycle 1
Number of Participants With Mutation, Deletion, Amplification in Phosphatidylinositol 3-kinase (PI3K) Pathway Signaling Related Genes and/or Proteins in Biopsied Tumor Tissue
Biopsied tumor tissue was analyzed for alterations in the phosphoinositide-3-kinase/rat sarcoma (PI3K/RAS) signaling pathway by molecular approaches. The biomarkers studied were PIK3CA and phosphatase and tensin homolog (PTEN) by immunohistochemistry.
Time frame: Baseline
Percentage of Participants With Objective Response (OR)
Objective response was defined as having complete response (CR) or Partial Response (PR) assessed by RECIST 1.1. CR was defined as disappearance of all target, non-target lesions; normalization of tumor marker level and all lymph nodes size was \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters). Percentage of participants with objective response were reported.
Time frame: Baseline until disease progression or death due to any cause (up to Cycle 14 [each cycle 28 days])
| Milestone | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 43 | 7 | 8 | 4 |
| Completed | 1 | 3 | 1 | 2 | 34 | 6 | 7 | 3 |
| Not completed | 3 | 1 | 3 | 2 | 9 | 1 | 1 | 1 |
| Withdrew: Death | 2 | 0 | 0 | 1 | 5 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Not treated due to disease related pain | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
| Participants | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| AEs | 4 | 4 | 4 | 4 | 42 | 7 | 8 | 4 |
| SAEs | 2 | 1 | 1 | 1 | 16 | 0 | 5 | 2 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Cycle 14, that were absent before treatment or that worsened relative to pretreatment state. Relatedness to drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category. AEs included both serious and non-serious adverse events.
| Participants | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| AEs | 3 | 3 | 4 | 4 | 40 | 7 | 8 | 4 |
| SAEs | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
Criteria for laboratory test abnormality: hematology (hemoglobin \[less than {\<} 0.8\*lower limit of normal {LLN}\], platelets \[\<0.5\*LLN or greater than {\>} 1.75\*upper limit of normal {ULN}\], white blood cells \[\<0.6\*LLN or \>1.5\*ULN\], lymphocytes \[\<0.8\*LLN or \>1.2\*ULN\], total neutrophils \[\<0.8\*LLN or \>1.2\*ULN\], basophils, eosinophils, monocytes \[\>1.2\*ULN\]); coagulation \[partial thromboplastin time, prothrombin (PT), PT international ratio \[\>1.1\*ULN\]); liver function (total bilirubin \[\>1.5\*ULN\], aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase \[\>0.3\*ULN\], total protein, albumin \[\<0.8\*LLN or \>1.2\*ULN\]).
| Participants | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 4 | 3 | 4 | 3 | 41 | 7 | 7 | 4 |
DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: Grade 3 nonhematologic AE (including nausea, vomiting, or diarrhea despite optimal therapy; or greater than or equal to \[\>=\] grade 3 asthenia \>2 days; or fasting serum glucose \>250 milligrams per deciliter (mg/dL) despite optimal therapy); \>=Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding; Grade 4 neutropenia lasting more than 7 days; Febrile neutropenia; other Grade 4 hematologic AE; delay of treatment \>2 consecutive weeks due to toxicity. Grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
| Participants | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 2 | 5 | 3 | 2 |
RP2D of PF-05212384 was determined based on the safety profile including laboratory and clinical assessments and pharmacodynamics findings.
| mg | PF-05212384 : All Participants |
|---|---|
| Recommended Phase-2 Dose (RP2D) | 154 |
| nanogram per milliliter (ng/mL) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 714.1 ± 33 | 1674 ± 10 | 3317 ± 10 | 6508 ± 106 | 9988 ± 28 | 14730 ± 54 | 14240 ± 29 | 27090 ± 26 |
| Cycle 2 | 542.8 ± 28 | 1482 ± 24 | 2601 ± 33 | 4250 ± 43 | 8594 ± 64 | 15660 ± 86 | 10840 ± 46 | NA ± NA |
Area under the plasma concentration versus time curve from time zero (predose) to time of last quantifiable concentration (Clast).
| nanogram*hour per milliliter(ng*hr/mL) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05212384: Single Dose | 1149 ± 35 | 2367 ± 24 | 5741 ± 14 | 13090 ± 77 | 15780 ± 28 | 26550 ± 30 | 28180 ± 36 | 46760 ± 2 |
Plasma decay half-life is the time measured for the plasma concentration of drug to decrease by one half.
| hours (hr) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 15.14 ± 6.1475 | 17.34 ± 9.8683 | 40.73 ± 7.7822 | 35.95 ± 9.1267 | 35.84 ± 6.2454 | 33.33 ± 4.8144 | 37.51 ± 4.8516 | 38.53 ± 4.5457 |
| Cycle 2 | — | NA ± NA | NA ± NA | 37.10 ± 4.4238 | 35.97 ± 5.3197 | 34.03 ± 6.6385 | 36.38 ± 5.1188 | NA ± NA |
AUCinf= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - inf).
| ng*hr/mL | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-05212384: Single Dose | 1238 ± 32 | 2485 ± 23 | 5881 ± 14 | 13280 ± 78 | 16250 ± 28 | 27210 ± 33 | 28280 ± 39 | 47460 ± 2 |
Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 168 hours (1 Week). For Cycle 2, the last PK sample for parameter calculations was on 120 hours after the Day 1 dose, however AUCtau was extrapolated to 168 hours using t1/2.
| ng*hr/mL | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 1256 ± 29 | 2604 ± 22 | 5753 ± 13 | 13100 ± 78 | 15810 ± 28 | 26740 ± 30 | 28220 ± 36 | 46730 ± 2 |
| Cycle 2 | 2991 ± 26 | NA ± NA | 15820 ± 29 | 25010 ± 49 | 47130 ± 54 | 79380 ± 64 | 61910 ± 42 | NA ± NA |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Number of Participants with maximum increase from baseline in QTcB and QTcF of \< 30 msec, between \<=30 to \<60 msec and \>=60 were reported.
| Participants | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| QTcB: Change <30 | 3 | 3 | 3 | 3 | 26 | 6 | 4 | 4 |
| QTcB: <= 30 and <60 | 1 | 1 | 1 | 0 | 13 | 1 | 3 | 0 |
| QTcB: Change >=60 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 |
| QTcF: Change <30 | 3 | 3 | 4 | 3 | 34 | 6 | 6 | 4 |
| QTcF: <= 30 and <60 | 1 | 1 | 0 | 0 | 7 | 1 | 2 | 0 |
| QTcF: Change >=60 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| milligram per deciliter (mg/dL) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Baseline | 100.3 ± 14.15 | 103.1 ± 14.55 | 87.0 ± 6.22 | 91.1 ± 7.40 | 95.6 ± 13.48 | 96.7 ± 10.85 | 88.4 ± 18.14 | 93.3 ± 3.06 |
| Change at Cycle 1 Day 2 | 12.5 ± 29.59 | -4.0 ± 7.07 | 0.3 ± 10.60 | 13.5 ± 4.08 | 13.7 ± 21.49 | 21.1 ± 24.97 | 65.5 ± 41.41 | 54.5 ± 94.71 |
| Change at Cycle 2 Day 1 | 1.0 ± 18.36 | 28.4 ± 26.90 | 11.5 ± 7.59 | 3.0 ± 9.56 | 2.8 ± 15.74 | 5.0 ± 6.67 | 12.9 ± 14.45 | 9.5 ± 3.54 |
| Change at Cycle 3 Day 1 | 19.0 ± NA | 19.0 ± NA | 2.0 ± NA | 9.3 ± 4.68 | 10.4 ± 29.02 | 16.0 ± 15.56 | 26.9 ± 33.77 | -11.0 ± 1.41 |
| Change at Cycle 4 Day 1 | -1.0 ± NA | 7.0 ± NA | 0.0 ± NA | 3.6 ± 7.64 | 2.0 ± 10.81 | 26.0 ± NA | 41.6 ± 45.85 | 6.5 ± 0.71 |
| Change at Cycle 5 Day 1 | -9.0 ± NA | 8.0 ± NA | — | 8.2 ± 8.78 | -3.8 ± 9.39 | -3.0 ± NA | 29.7 ± 33.08 | -7.0 ± 2.83 |
| Change at Cycle 6 Day 1 | -7.0 ± NA | 2.0 ± NA | — | 1.0 ± 1.41 | -10.0 ± 8.66 | 14.0 ± NA | 29.1 ± 28.17 | 5.0 ± 5.66 |
| Change at Cycle 7 Day 1 | -9.0 ± NA | 10.0 ± NA | — | 8.0 ± NA | -5.0 ± 2.83 | — | 48.7 ± 50.13 | 7.0 ± NA |
| Change at Cycle 8 Day 1 | -12.0 ± NA | 6.0 ± NA | — | 11.0 ± NA | 1.5 ± 21.92 | — | 39.0 ± 32.70 | -3.0 ± NA |
| Change at Cycle 9 Day 1 | -7.0 ± NA | 9.0 ± NA | — | 5.0 ± NA | — | — | 65.0 ± 42.66 | 1.0 ± NA |
| Change at Cycle 10 Day 1 | -2.0 ± NA | 15.0 ± NA | — | — | — | — | — | 11.0 ± NA |
| Change at Cycle 11 Day 1 | -8.0 ± NA | -15.0 ± NA | — | — | — | — | 39.6 ± NA | — |
| Change at Cycle 12 Day 1 | -9.0 ± NA | — | — | — | — | — | 28.8 ± NA | — |
| Change at Cycle 13 Day 1 | — | — | — | — | — | — | -1.8 ± NA | — |
| Change at Cycle 14 Day 1 | — | — | — | — | — | — | 36.0 ± NA | — |
| Change at EOT | 10.7 ± 34.12 | 7.2 ± 12.64 | 23.3 ± 31.48 | 16.1 ± 15.07 | 7.4 ± 21.08 | -6.7 ± 13.52 | 27.5 ± 32.75 | 42.0 ± 72.12 |
| microunits per milliliter (mcU/mL) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Baseline ( n=4,1,3,2,35,4,4,3) | 23.8 ± 22.90 | 10.2 ± NA | 8.6 ± 4.40 | 5.3 ± 1.84 | 13.1 ± 9.34 | 18.2 ± 14.14 | 5.9 ± 7.86 | 11.4 ± 7.00 |
| Change at Cycle 1 Day 2 (n =4,1,3,2,37,6,7,4) | 4.0 ± 33.56 | 2.5 ± NA | 2.9 ± 6.81 | 4.7 ± 2.90 | 22.8 ± 25.68 | 40.9 ± 47.05 | 57.5 ± 41.66 | 110.3 ± 117.23 |
| Change at Cycle 2 Day 1 (n =0,0,0,2,27,5,3,1) | — | — | — | 5.4 ± 3.54 | 1.3 ± 8.66 | 2.6 ± 7.88 | 7.3 ± 10.31 | -2.9 ± NA |
| Change at Cycle 3 Day 1 (n =0,1,1,1,14,1,3,1) | — | 1.4 ± NA | 2.1 ± NA | 0.9 ± NA | -0.7 ± 11.66 | 4.2 ± NA | 2.1 ± 4.38 | 18.0 ± NA |
| Change at Cycle 4 Day 1 (n =0,0,1,1,8,0,3,2) | — | — | 3.1 ± NA | 3.0 ± NA | 2.9 ± 6.35 | — | 4.2 ± 2.54 | 0.6 ± 3.32 |
| Change at Cycle 5 Day 1 (n =0,1,0,1,5,0,3,1) | — | -0.7 ± NA | — | 0.1 ± NA | 2.3 ± 5.24 | — | 3.3 ± 1.86 | -3.0 ± NA |
| Change at C6D1 (n=0,1,0,1,3,0,2,2) | — | -1.2 ± NA | — | 3.1 ± NA | 0.9 ± 5.14 | — | 0.8 ± 0.07 | 0.3 ± 0.42 |
| Change at Cycle 7 Day 1 (n=0,1,0,1,2,0,3,1) | — | 0.9 ± NA | — | 0.2 ± NA | 2.1 ± 0.85 | — | 6.9 ± 8.31 | 5.0 ± NA |
| Change at Cycle 8 Day 1 (n =0,1,0,1,2,0,3,1) | — | -1.9 ± NA | — | 3.1 ± NA | 4.5 ± 4.17 | — | -0.9 ± 2.71 | -1.4 ± NA |
| Change at Cycle 9 Day 1 ( n=0,1,0,1,0,0,2,1) | — | 5.0 ± NA | — | 0.9 ± NA | — | — | 1.8 ± 4.60 | -1.7 ± NA |
| Change at Cycle 10 Day 1 (n =1,1,0,0,0,0,0,1) | -18.3 ± NA | 3.4 ± NA | — | — | — | — | — | 5.8 ± NA |
| Change at Cycle 11 Day 1 (n =1,1,0,0,0,0,1,0) | -32.2 ± NA | 0.1 ± NA | — | — | — | — | 38.6 ± NA | — |
| Change at Cycle 12 Day 1 (n =1,0,0,0,0,0,0,0) | -4.3 ± NA | — | — | — | — | — | — | — |
| Change at Cycle 13 D 1 (n =0,0,0,0,0,0,1,0) | — | — | — | — | — | — | 22.0 ± NA | — |
| Change at Cycle 14 Day 1 (n =0,0,0,0,0,0,1,0) | — | — | — | — | — | — | 107.0 ± NA | — |
| Change at EOT (n =1,0,1,1,21,4,6,1) | 19.1 ± NA | — | 0.0 ± NA | 0.8 ± NA | 1.7 ± 8.59 | -4.8 ± 9.04 | 19.6 ± 21.67 | -4.3 ± NA |
| ng/mL | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg |
|---|---|---|---|
| Baseline | 3.0 ± 1.82 | 3.0 ± 1.19 | 4.6 ± 1.92 |
| Change at Cycle 1 Day 2 | 3.6 ± 2.23 | 6.2 ± 4.23 | 5.0 ± 5.37 |
| Change at Cycle 2 Day 1 | 0.4 ± 1.36 | 1.0 ± 1.30 | -1.1 ± 2.23 |
| Change at Cycle 3 Day 1 | 0.5 ± 1.15 | 2.5 ± NA | -1.8 ± 3.11 |
| Change at Cycle 4 Day 1 | 0.9 ± 1.45 | — | 0.1 ± 1.56 |
| Change at Cycle 5 Day 1 | 0.4 ± 0.86 | — | -1.2 ± 2.87 |
| Change at Cycle 6 Day 1 | -0.0 ± 0.54 | — | -0.3 ± 1.60 |
| Change at Cycle 7 Day 1 | 0.1 ± 0.36 | — | 1.9 ± 1.20 |
| Change at Cycle 8 Day 1 | 0.3 ± 0.14 | — | -0.9 ± 3.75 |
| Change at Cycle 9 Day 1 | — | — | 2.9 ± NA |
| Change at EOT | 1.1 ± 1.82 | -0.1 ± 0.80 | 5.3 ± 1.68 |
Analysis of hair follicles was conducted using a Reverse Phase Microarrays (RPMA) assay. Phosphoprotein biomarkers measured were pAkt S473, pAkt T308, pStat3 (Y705), Ki-67, and pPRAS40 (T246).
| normalized fluorescence units (NFU) | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg |
|---|---|---|---|
| Baseline: pAkt S473 | 12.2 ± 4.58 | 17.2 ± 5.26 | — |
| Baseline: pAkt T308 | 44.3 ± 19.41 | 36.2 ± 15.95 | — |
| Baseline: pStat3 (Y705) | 172.3 ± 47.26 | 224.2 ± 117.43 | — |
| Baseline: Ki-67 | 82.1 ± 21.79 | 128.1 ± 30.80 | 145.7 ± NA |
| Baseline: pPRAS40 (T246) | 111.7 ± 31.75 | 99.6 ± 30.11 | — |
| Change at C1D1 2H:pAkt S473 | -1.7 ± 3.59 | 6.8 ± 5.77 | — |
| Change at C1D1 2H:pAkt T308 | 2.3 ± 17.06 | -4.6 ± NA | — |
| Change at C1D1 2H:pStat3 (Y705) | -6.2 ± 34.78 | 126.3 ± NA | — |
| Change at C1D1 2H:Ki-67 | 1.0 ± 29.41 | 34.7 ± NA | -36.2 ± NA |
| Change at C1D1 2H:pPRAS40-T246 | -27.4 ± 22.59 | 42.0 ± 26.01 | — |
| Change at C1D1 3hr: pAkt S473 | -0.9 ± 2.93 | 0.2 ± 9.26 | — |
| Change at C1D1 3hr: pAkt T308 | 0.4 ± 14.25 | 6.9 ± 18.50 | — |
| Change at C1D1 3H: pStat3 (Y705) | -11.7 ± 54.88 | -142.2 ± NA | — |
| Change at C1D1 3hr: Ki-67 | -8.5 ± 23.59 | 25.2 ± 15.68 | — |
| Change at C1D1 3H:pPRAS40-T246 | -27.8 ± 27.11 | 49.8 ± 56.37 | — |
| Change at C1D4 72H:pAkt S473 | -0.9 ± 3.69 | 1.7 ± 9.45 | — |
| Change at C1D4 72H:pAkt-T308 | 9.4 ± 38.19 | 11.8 ± 15.16 | — |
| Change at C1D4 72H: pStat3 (Y705) | 1.9 ± 35.99 | 239.8 ± NA | — |
| Change at C1D4 72hr: Ki-67 | 5.7 ± 38.59 | 13.5 ± 57.80 | — |
| Change atC1D4-72H:pPRAS40 T246 | -2.1 ± 31.55 | 35.6 ± 77.10 | — |
Tumor biopsies were taken from participants of reporting arm PF-05212384 154 mg dose level at baseline and at Cycle 1/Day 22. Biopsies were fixed in optimal cutting temperature compound and analyzed via RPMA. The biomarkers tested were phosphorylated versions of the proteins: AKT S473, AKT T308, FKHR T24 / FKHR1 T32, and STAT3. This outcome measure was planned to be analyzed only for the reporting arm Part 1 and 2: PF-05212384 154 mg, as pre-specified in protocol.
| normalized to cytokeratin (NFC) | Part 1 and 2: PF-05212384 154 mg |
|---|---|
| Baseline: AKT S473 | 34.3 ± 26.82 |
| Baseline: AKT T308 | 38.5 ± 25.80 |
| Baseline: FKHR T24 / FKHR1 T32 | 145.1 ± 113.99 |
| Baseline: STAT3 | 231.4 ± 219.22 |
| Change at C1D22: AKT S473 | -12.3 ± 36.88 |
| Change at C1D22: AKT T308 | -5.8 ± 25.42 |
| Change at C1D22: FKHR T24 / FKHR1 T32 | -27.0 ± 82.92 |
| Change at C1D22: STAT3 | -45.6 ± 139.67 |
Biopsied tumor tissue was analyzed for alterations in the phosphoinositide-3-kinase/rat sarcoma (PI3K/RAS) signaling pathway by molecular approaches. The biomarkers studied were PIK3CA and phosphatase and tensin homolog (PTEN) by immunohistochemistry.
| Participants | PF-05212384 : All Participants |
|---|---|
| PTEN Mutation: Present | NA |
| PTEN Mutation: Absent | NA |
| PTEN Deletion: Present | 28 |
| PTEN Deletion: Absent | 28 |
| PTEN Amplification: Present | NA |
| PTEN Amplification: Absent | NA |
| PIK3CA Mutation: Present | 4 |
| PIK3CA Mutation: Absent | 27 |
| PIK3CA Deletion: Present | NA |
| PIK3CA Deletion: Absent | NA |
| PIK3CA Amplification: Present | 2 |
| PIK3CA Amplification: Absent | 56 |
Objective response was defined as having complete response (CR) or Partial Response (PR) assessed by RECIST 1.1. CR was defined as disappearance of all target, non-target lesions; normalization of tumor marker level and all lymph nodes size was \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters). Percentage of participants with objective response were reported.
| percentage of participants | PF-05212384 : All Participants |
|---|---|
| Percentage of Participants With Objective Response (OR) | 2.6 (0.3 to 9.1) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: PF-05212384 10 mg | — | 2/4 (50%) | 4/4 (100%) |
| Part 1: PF-05212384 21 mg | — | 1/4 (25%) | 4/4 (100%) |
| Part 1: PF-05212384 43 mg | — | 1/4 (25%) | 4/4 (100%) |
| Part 1: PF-05212384 89 mg | — | 1/4 (25%) | 4/4 (100%) |
| Part 1 and 2: PF-05212384 154 mg | — | 16/42 (38.1%) | 42/42 (100%) |
| Part 1: PF-05212384 222 mg | — | 0/7 (0%) | 7/7 (100%) |
| Part 1: PF-05212384 266 mg | — | 5/8 (62.5%) | 8/8 (100%) |
| Part 1: PF-05212384 319 mg | — | 2/4 (50%) | 4/4 (100%) |
| Event | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 2/4 | 0/4 | 0/4 | 0/4 | 3/42 | 0/7 | 1/8 | 0/4 |
| Abdominal painGastrointestinal disorders | 1/4 | 0/4 | 0/4 | 0/4 | 1/42 | 0/7 | 0/8 | 1/4 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/42 | 0/7 | 0/8 | 1/4 |
| VomitingGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/42 | 0/7 | 0/8 | 1/4 |
| Mucosal inflammationGeneral disorders | 0/4 | 0/4 | 0/4 | 0/4 | 1/42 | 0/7 | 0/8 | 1/4 |
| PneumoniaInfections and infestations | 0/4 | 0/4 | 0/4 | 1/4 | 0/42 | 0/7 | 1/8 | 0/4 |
| Respiratory tract infectionInfections and infestations | 0/4 | 1/4 | 0/4 | 0/4 | 0/42 | 0/7 | 1/8 | 0/4 |
| Septic shockInfections and infestations | 0/4 | 0/4 | 0/4 | 1/4 | 0/42 | 0/7 | 0/8 | 0/4 |
| Humerus fractureInjury, poisoning and procedural complications | 0/4 | 0/4 | 1/4 | 0/4 | 0/42 | 0/7 | 0/8 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/42 | 0/7 | 0/8 | 1/4 |
| Event | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/4 | 2/4 | 2/4 | 1/4 | 22/42 | 3/7 | 6/8 | 3/4 |
| VomitingGastrointestinal disorders | 3/4 | 1/4 | 0/4 | 0/4 | 15/42 | 2/7 | 5/8 | 1/4 |
| FatigueGeneral disorders | 3/4 | 2/4 | 2/4 | 0/4 | 10/42 | 3/7 | 3/8 | 2/4 |
| Mucosal inflammationGeneral disorders | 0/4 | 1/4 | 1/4 | 0/4 | 19/42 | 5/7 | 6/8 | 3/4 |
| Blood alkaline phosphatase increasedInvestigations | 3/4 | 0/4 | 1/4 | 0/4 | 6/42 | 0/7 | 0/8 | 0/4 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/4 | 0/4 | 1/4 | 0/4 | 12/42 | 1/7 | 4/8 | 3/4 |
| RashSkin and subcutaneous tissue disorders | 0/4 | 0/4 | 1/4 | 3/4 | 6/42 | 0/7 | 6/8 | 2/4 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 1/4 | 1/4 | 1/4 | 6/42 | 1/7 | 2/8 | 2/4 |
| LymphopeniaBlood and lymphatic system disorders | 0/4 | 0/4 | 1/4 | 0/4 | 4/42 | 0/7 | 0/8 | 2/4 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 1/4 | 0/4 | 2/4 | 9/42 | 2/7 | 2/8 | 2/4 |
Safety analysis set included all participants who received at least 1 dose of study medication.
| Age, Categorical(Participants) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 3 | 4 | 4 | 34 | 4 | 7 | 4 | 64 |
| >=65 years | 0 | 1 | 0 | 0 | 8 | 3 | 1 | 0 | 13 |
| Sex: Female, Male(Participants) | Part 1: PF-05212384 10 mg | Part 1: PF-05212384 21 mg | Part 1: PF-05212384 43 mg | Part 1: PF-05212384 89 mg | Part 1 and 2: PF-05212384 154 mg | Part 1: PF-05212384 222 mg | Part 1: PF-05212384 266 mg | Part 1: PF-05212384 319 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 3 | 1 | 2 | 20 | 5 | 4 | 4 | 40 |
| Male | 3 | 1 | 3 | 2 | 22 | 2 | 4 | 0 | 37 |
Ran from Jan 2010 to primary completion in Aug 2011, 19 months.
Results were first posted in Nov 2018, 7 years 3 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 19 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gedatolisib